CHINARES PHARMA

3320
4.4902.16% ( +0.095 )
Delay Closed: Nov 16, 16:08:11

Valuation

Current ValuationThe current P/E ratio is 5.90, below the reasonable range, cheaper than 96.63% of the time in the past 5 years, and the industry ranks 3/53, the industry Median 6.94.

5.9xP/E
Stock priceHK$4.49Earnings per shareHK$0.76

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.94x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.94x
0x20x40x60x80x100x
P/E ratio
Name/Symbol
03320HKCHINARES PHARMA
5.90x7.23%HK$28.21B
01681HKCONSUN PHARMA
9.90x20.92%HK$13.39B
02877HKSHINEWAY PHARM
6.94x13.28%HK$6.43B
02186HKLUYE PHARMA
7.70x47.27%HK$6.17B
02633HKJACOBSON PHARMA
6.00x1.99%HK$1.81B
08049HKJILIN CHANGLONG
6.47x--HK$1.63B
02348HKDAWNRAYS PHARMA
5.02x--HK$1.34B
02161HKJBM HEALTHCARE
6.15x6.78%HK$1.24B
00239HKPAK FAH YEOW
7.45x--HK$737.03M
00950HKLEE'S PHARM
4.97x--HK$594.72M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.